AtriCure Inc. (NASDAQ:ATRC) Director Elizabeth D. Krell Sells 10,000 Shares

AtriCure Inc. (NASDAQ:ATRC) Director Elizabeth D. Krell sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

ATRC stock traded down $0.13 during midday trading on Friday, hitting $19.93. The stock had a trading volume of 193,911 shares, compared to its average volume of 209,047. The stock has a market cap of $693.28, a P/E ratio of -24.01 and a beta of 0.26. AtriCure Inc. has a 52 week low of $14.88 and a 52 week high of $25.18. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.58 and a quick ratio of 1.87.

How to Become a New Pot Stock Millionaire

AtriCure (NASDAQ:ATRC) last issued its earnings results on Monday, February 26th. The medical device company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.13. The firm had revenue of $46.06 million during the quarter, compared to analysts’ expectations of $45.85 million. AtriCure had a negative return on equity of 16.74% and a negative net margin of 15.39%. AtriCure’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period last year, the business earned ($0.27) earnings per share. equities research analysts anticipate that AtriCure Inc. will post -0.83 EPS for the current year.

Several brokerages have recently issued reports on ATRC. BidaskClub upgraded shares of AtriCure from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 15th. ValuEngine upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Canaccord Genuity raised their target price on AtriCure from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price (down from $25.00) on shares of AtriCure in a research report on Tuesday, January 16th. Finally, TheStreet raised AtriCure from a “d+” rating to a “c-” rating in a research report on Friday, March 16th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. AtriCure has an average rating of “Buy” and an average target price of $24.80.

Several hedge funds and other institutional investors have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new position in shares of AtriCure during the fourth quarter valued at $297,000. Macquarie Group Ltd. lifted its holdings in shares of AtriCure by 21.7% during the fourth quarter. Macquarie Group Ltd. now owns 100,056 shares of the medical device company’s stock valued at $1,825,000 after acquiring an additional 17,811 shares during the period. Vident Investment Advisory LLC bought a new position in shares of AtriCure during the fourth quarter valued at $502,000. Kopp Investment Advisors LLC lifted its holdings in shares of AtriCure by 11.2% during the fourth quarter. Kopp Investment Advisors LLC now owns 127,435 shares of the medical device company’s stock valued at $2,324,000 after acquiring an additional 12,836 shares during the period. Finally, HBK Investments L P bought a new position in shares of AtriCure during the fourth quarter valued at $255,000. 87.50% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/elizabeth-d-krell-sells-10000-shares-of-atricure-inc-atrc-stock.html.

AtriCure Company Profile

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply